PIPELINE

GRX-917 works by inducing the production of endogenous neurosteroids (such as allopregnanolone) and inhibiting NLRP3 inflammation. These important mechanisms of action could benefit a broad range of neuropsychiatric, neurological and auto-immune disorders. GRX-917 is ready to initiate Phase 2/3 registration studies in anxiety in 2025 and potentially a broad range of other indications.